U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H33N5O10
Molecular Weight 647.6319
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IDETREXED

SMILES

OCC1=NC2=C(C=C3[C@H](CCC3=C2)N(CC#C)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(=O)N[C@H](CCC(O)=O)C(O)=O)C(O)=O)C(=O)N1

InChI

InChIKey=NVHRBQOZEMFKLD-CUYJMHBOSA-N
InChI=1S/C32H33N5O10/c1-2-13-37(25-10-5-18-14-24-21(15-20(18)25)30(43)36-26(16-38)33-24)19-6-3-17(4-7-19)29(42)35-23(32(46)47)8-11-27(39)34-22(31(44)45)9-12-28(40)41/h1,3-4,6-7,14-15,22-23,25,38H,5,8-13,16H2,(H,34,39)(H,35,42)(H,40,41)(H,44,45)(H,46,47)(H,33,36,43)/t22-,23+,25+/m1/s1

HIDE SMILES / InChI

Molecular Formula C32H33N5O10
Molecular Weight 647.6319
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 10:53:24 GMT 2023
Edited
by admin
on Sat Dec 16 10:53:24 GMT 2023
Record UNII
Q718FS1C7X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IDETREXED
INN  
Official Name English
idetrexed [INN]
Common Name English
D-GLUTAMIC ACID, N-(4-(2-PROPYNYL((6S)-4,6,7,8-TETRAHYDRO-2-(HYDROXYMETHYL)-4-OXO-1H-CYCLOPENTA(G)QUINAZOLIN-6-YL)AMINO)BENZOYL)-L-.GAMMA.-GLUTAMYL-
Common Name English
N-(4-(2-PROPYN-1-YL((6S)-4,6,7,8-TETRAHYDRO-2-(HYDROXYMETHYL)-4-OXO-3H-CYCLOPENTA(G)QUINAZOLIN-6-YL)AMINO)BENZOYL)-L-.GAMMA.-GLUTAMYL-D-GLUTAMIC ACID
Systematic Name English
CB-300945 (S)
Code English
ONX-0801
Code English
6S-BGC-945
Code English
BGC-945
Code English
Idetrexed [WHO-DD]
Common Name English
Code System Code Type Description
CAS
501332-69-0
Created by admin on Sat Dec 16 10:53:24 GMT 2023 , Edited by admin on Sat Dec 16 10:53:24 GMT 2023
PRIMARY
PUBCHEM
135487419
Created by admin on Sat Dec 16 10:53:24 GMT 2023 , Edited by admin on Sat Dec 16 10:53:24 GMT 2023
PRIMARY
FDA UNII
Q718FS1C7X
Created by admin on Sat Dec 16 10:53:24 GMT 2023 , Edited by admin on Sat Dec 16 10:53:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID701337116
Created by admin on Sat Dec 16 10:53:24 GMT 2023 , Edited by admin on Sat Dec 16 10:53:24 GMT 2023
PRIMARY
NCI_THESAURUS
C120550
Created by admin on Sat Dec 16 10:53:24 GMT 2023 , Edited by admin on Sat Dec 16 10:53:24 GMT 2023
PRIMARY
WIKIPEDIA
ONX-0801
Created by admin on Sat Dec 16 10:53:24 GMT 2023 , Edited by admin on Sat Dec 16 10:53:24 GMT 2023
PRIMARY
INN
11325
Created by admin on Sat Dec 16 10:53:24 GMT 2023 , Edited by admin on Sat Dec 16 10:53:24 GMT 2023
PRIMARY
SMS_ID
100000184029
Created by admin on Sat Dec 16 10:53:24 GMT 2023 , Edited by admin on Sat Dec 16 10:53:24 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Affinity of BGC 945 for the A-FR is 70% of the high-affinity ligand folic acid. In contrast to conventional antifolates, BGC 945 has low affinity for the widely expressed reduced-folate carrier (RFC).In contrast, BGC 945 is highly potent in a range of A-FR-overexpressing human tumor cell lines (IC50 f1-300 nmol/L). Pharmacokinetic variables measured following i.v. injection of 100 mg/kg BGC 945 to KB tumorbearing mice showed rapid plasma clearance (0.021 L/h) and tissue distribution. The terminal half-lives in plasma, liver, kidney, spleen, and tumor were 2, 0.6, 5, 21, and 28 hours, respectively.
ACTIVE MOIETY
Originator: BTG, The Institute of Cancer Research; Developer: Onyx Pharmaceuticals, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research; Class: Antineoplastic, Quinazoline; Mechanism of Action: Thymidylate synthase inhibitor; Highest Development Phase: Phase I for Solid tumours; Most Recent Events: 11 Mar 2016 Phase-I development is ongoing in United Kingdom, 01 Oct 2013 Onyx Pharmaceuticals has been acquired by Amgen, 31 Mar 2011 Onyx Pharmaceuticals completes a Phase-I trial in Solid tumours in United Kingdom (ISRCTN79302332)